Imatinib Stada (Imatinib)

Imatinib acts on malignant cells that depend on BCR‑ABL, c‑KIT or PDGFR signaling pathways.

• Chronic myeloid leukemia (CML): suppresses leukemic cell proliferation and induces remission.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): improves survival by targeting the BCR‑ABL fusion protein.
• Gastrointestinal stromal tumor (GIST): inhibits c‑KIT driven tumor growth.
• Other BCR‑ABL positive hematologic malignancies: provides disease control where BCR‑ABL drives pathology.

• Imatinib selectively inhibits the ATP‑binding site of BCR‑ABL tyrosine kinase as well as the related kinases c‑KIT and platelet‑derived growth factor receptor (PDGFR). By blocking these enzymes, it prevents downstream phosphorylation events that drive uncontrolled cell division, thereby reducing proliferation of malignant cells and promoting apoptosis in susceptible tumor populations.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often of the hands or feet.
• Fatigue: generalized tiredness.
• Diarrhea: loose stools, usually self‑limiting.
• Muscle cramps: intermittent skeletal muscle discomfort.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or jaundice.
• Cardiotoxicity: decreased left‑ventricular ejection fraction.
• Severe neutropenia: markedly reduced white‑blood cell count increasing infection risk.

Before initiating therapy, clinicians should assess baseline organ function and monitor throughout treatment.

• Baseline labs: obtain complete blood count, liver and renal function tests.
• Cardiac monitoring: evaluate ejection fraction in patients with pre‑existing heart disease.
• Drug interactions: review concomitant medications that affect CYP3A4 metabolism.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
• Patient counseling: advise on signs of infection, bleeding, or liver dysfunction.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Imatinib may interact with several agents that alter its plasma concentration or pharmacodynamic profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce efficacy.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase toxicity risk.

Moderate Interactions (Monitor Closely)

• Acid‑suppressing agents (e.g., proton pump inhibitors, antacids): may affect absorption.
• Concomitant anticoagulants (e.g., warfarin): monitor INR for potential bleeding.
• Vaccines: live attenuated vaccines should be avoided during treatment.